Top Phage Therapy Companies

Global Phage Therapy Market size was valued at USD 34.99 Million in 2024 and is poised to grow from USD 41.07 Million in 2025 to USD 148.22 Million by 2033, growing at a CAGR of 17.4% during the forecast period (2026–2033).

The highly competitive phage therapy market dynamics of the global stage are fueled by government funding, regulatory advancements, and collaboration strategies. Backed by large grants from the National Institutes of Health (NIH), Locus Biosciences and Adaptive Phage Therapeutics (APT) are spearheading the US towards developing individualized phage treatments. In Europe, Belgium has pioneered regulatory frameworks, such as magistral preparation, to make phage therapies accessible to the public. Moreover, the UK government is adding phage therapy to its 2024–2029 Antimicrobial Resistance National Action Plan. All these developments indicate a worldwide trend towards the integration of phage therapy into mainstream clinical practice. 'Armata Pharmaceuticals (United States)', 'BiomX Inc. (Israel)', 'Intralytix (United States)', 'Locus Biosciences (United States)', 'Amplify Biosciences (United States)', 'EnBiotix (United States)', 'PhagoMed Biopharma (Austria)', 'Transgene S.A. (France)', 'Imugene Ltd (Australia)', 'Evotec SE (Germany)', 'Novolytics (United Kingdom)', 'GangaGen Biotechnologies (India)', 'Pherecydes Pharma (France)', 'Eligo Bioscience (France)', 'Micreos (Netherlands)', 'ContraFect Corporation (United States)', 'Phagomed Biopharma GmbH (Austria)', 'PhagePro Inc. (United States)', 'TechnoPhage (Portugal)', 'Intralytix, Inc. (United States)'

Antimicrobial (AMR) resistance occurs because bacteria become resistant to drugs that initially killed them, and this makes infections harder to treat. Misuse and overuse of antibiotics introduce the emergence of AMR due to increased mortality, disease spread, and higher healthcare cost. As quoted by the World Health Organization, a maximum of 10 million deaths every year in 2050 is attributed to AMR, hence additional therapies such as phage therapy will be in demand.Increasing Incidence of Chronic Infections.

Short-Term: To enhance treatment specificity and efficacy, phage therapy developers are increasingly implementing AI and bioinformatics at a fast pace. AI-assisted phage-host prediction programs and phage screening platforms automate the process at an accelerated speed. These facilities cut down the time required for development, costs, and also improve therapeutic specificity, thus paving the way for phage therapy to be increasingly implemented in personalized medicine.

North America has the highest percentage share of the overall phage therapy market, standing at around 40–45% of revenue. This can be explained by the large research efforts that receive government funding as well as by a strong health infrastructure. The National Institutes of Health (NIH), for example, has been actively supporting phage therapy research, such as programs like the R01AI169865 award, towards the creation of phage-based therapeutics for biofilm-related infections. Such investment highlights the area's emphasis on developing phage therapy as a potential alternative to conventional antibiotics.